Overview

Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma

Status:
Not yet recruiting

Trial end date:
2028-06-01

Target enrollment:

Participant gender:

Summary

This is a multicenter, randomized (2:1), open-label, controlled Phase 3 trial of XL092 in combination with nivolumab versus sunitinib in subjects with unresectable, locally advanced or metastatic nccRCC who have not received prior systemic anticancer therapy.

Phase:

Phase 3

Details

Lead Sponsor:

Exelixis

Treatments:

Nivolumab
Sunitinib